PE20160037A1 - Formulacion farmaceutica que comprende fosfatidilcolina para el tratamiento de colitus ulcerosa - Google Patents

Formulacion farmaceutica que comprende fosfatidilcolina para el tratamiento de colitus ulcerosa

Info

Publication number
PE20160037A1
PE20160037A1 PE2015002052A PE2015002052A PE20160037A1 PE 20160037 A1 PE20160037 A1 PE 20160037A1 PE 2015002052 A PE2015002052 A PE 2015002052A PE 2015002052 A PE2015002052 A PE 2015002052A PE 20160037 A1 PE20160037 A1 PE 20160037A1
Authority
PE
Peru
Prior art keywords
acid
pharmaceutical formulation
treatment
colitus
ulcerosa
Prior art date
Application number
PE2015002052A
Other languages
English (en)
Inventor
Gerhard Keilhauer
Original Assignee
Lipid Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipid Therapeutics Gmbh filed Critical Lipid Therapeutics Gmbh
Publication of PE20160037A1 publication Critical patent/PE20160037A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a una formulacion farmaceutica, que comprende un producto de fosfatidilcolina (PC) de formula (I), donde R¹ es el residuo de un acido graso saturado o no saturado con 12 a 24 atomos de carbono, y R² es el residuo de un acido graso saturado o no saturado con 12 a 24 atomos de carbono, y donde el producto de fosfatidilcolina (PC) contiene las siguientes cantidades de acidos grasos: 55 - 72 acido linoleico, 10 - 18 acido palmitico, 07 - 15 acido oleico, 02 - 08 acido linolenico, 02 - 08 acido estearico; y al menos un excipiente para liberacion retardada puede ser usado para el tratamiento mejorado de colitis ulcerosa
PE2015002052A 2013-03-26 2014-03-25 Formulacion farmaceutica que comprende fosfatidilcolina para el tratamiento de colitus ulcerosa PE20160037A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13161089 2013-03-26

Publications (1)

Publication Number Publication Date
PE20160037A1 true PE20160037A1 (es) 2016-02-04

Family

ID=47913311

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002052A PE20160037A1 (es) 2013-03-26 2014-03-25 Formulacion farmaceutica que comprende fosfatidilcolina para el tratamiento de colitus ulcerosa

Country Status (26)

Country Link
US (1) US20160045523A1 (es)
EP (1) EP2978416B1 (es)
JP (1) JP6262843B2 (es)
KR (1) KR20150132841A (es)
CN (1) CN105377247B (es)
AU (1) AU2014243102B2 (es)
BR (1) BR112015023849A2 (es)
CA (1) CA2907401A1 (es)
CL (1) CL2015002832A1 (es)
DK (1) DK2978416T3 (es)
EA (1) EA029514B1 (es)
ES (1) ES2605650T3 (es)
HK (1) HK1217089A1 (es)
HU (1) HUE030707T2 (es)
IL (1) IL241019A0 (es)
LT (1) LT2978416T (es)
MD (1) MD20150089A2 (es)
MX (1) MX2015013511A (es)
PE (1) PE20160037A1 (es)
PH (1) PH12015502199A1 (es)
PL (1) PL2978416T3 (es)
PT (1) PT2978416T (es)
SG (1) SG11201507777TA (es)
UA (1) UA115585C2 (es)
WO (1) WO2014154683A1 (es)
ZA (1) ZA201507910B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA105037C2 (uk) 2009-02-16 2014-04-10 Джуліані Інтернешнл Лімітед Способи лікування патологічних станів, пов'язаних з волоссям
CA2864059C (en) 2012-02-09 2020-04-28 Nogra Pharma Limited Methods of treating fibrosis
EP3419616A1 (en) * 2016-02-26 2019-01-02 Nogra Pharma Limited Methods of treating lactose intolerance
KR20210125047A (ko) 2019-02-08 2021-10-15 노그라 파마 리미티드 3-(4'-아미노페닐)-2-메톡시프로피온산, 및 그의 유사체 및 중간체의 제조 방법
US20220162238A1 (en) * 2019-03-05 2022-05-26 Sichuan Gowell Pharmaceutical Co., Ltd. Fatty acid composition and application thereof
CN113368118B (zh) * 2021-07-21 2022-09-23 中国药科大学 磷脂酰胆碱在制备治疗溃疡性结肠炎的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3022136C2 (de) * 1980-06-13 1986-07-17 A. Nattermann & Cie GmbH, 5000 Köln Verfahren zum Abfüllen von Phospholipide enthaltenden pharmazeutischen Massen in Hartkapseln
US4560655A (en) * 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
IT1243981B (it) * 1990-10-01 1994-06-28 Fidia Spa Composizioni per il trattamento della pelle contenenti derivati della b-fosfatidilcolina
US5453523A (en) * 1993-06-16 1995-09-26 Emulsion Technology, Inc. Process for obtaining highly purified phosphatidylcholine
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
DK1105141T3 (da) * 1998-08-06 2004-03-08 Wolfgang Stremmel Phosphatidylcholin som et medikament med slimhindebeskyttende virkning
ES2452351T3 (es) * 2007-07-31 2014-04-01 Pat Gmbh Uso de fosfatidilcolina para el tratamiento de colitis ulcerosa dependiente de esteroides y refractaria a esteroides
CN102633832B (zh) * 2011-02-09 2015-07-22 北京绿色金可生物技术股份有限公司 一种制备高纯度磷脂酰胆碱的方法

Also Published As

Publication number Publication date
IL241019A0 (en) 2015-11-30
PT2978416T (pt) 2016-12-09
JP6262843B2 (ja) 2018-01-17
MX2015013511A (es) 2016-06-28
ES2605650T3 (es) 2017-03-15
CA2907401A1 (en) 2014-10-02
JP2016516087A (ja) 2016-06-02
AU2014243102B2 (en) 2018-04-26
HK1217089A1 (zh) 2016-12-23
CN105377247B (zh) 2019-04-26
BR112015023849A2 (pt) 2017-07-18
CN105377247A (zh) 2016-03-02
UA115585C2 (uk) 2017-11-27
ZA201507910B (en) 2017-04-26
AU2014243102A1 (en) 2015-09-17
HUE030707T2 (en) 2017-05-29
LT2978416T (lt) 2016-12-12
MD20150089A2 (ro) 2016-03-31
DK2978416T3 (en) 2016-12-19
SG11201507777TA (en) 2015-10-29
PL2978416T3 (pl) 2017-03-31
KR20150132841A (ko) 2015-11-26
EA029514B1 (ru) 2018-04-30
CL2015002832A1 (es) 2016-03-11
US20160045523A1 (en) 2016-02-18
PH12015502199A1 (en) 2016-01-25
EP2978416B1 (en) 2016-10-26
EP2978416A1 (en) 2016-02-03
WO2014154683A1 (en) 2014-10-02
EA201591510A1 (ru) 2016-01-29

Similar Documents

Publication Publication Date Title
PE20160037A1 (es) Formulacion farmaceutica que comprende fosfatidilcolina para el tratamiento de colitus ulcerosa
CL2019003105A1 (es) Lípidos extraídos de plantas que comprenden ácidos grasos poliinsaturados de cadena larga. (divisional solicitud 201601560)
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
AR088983A1 (es) Procedimiento para la preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
WO2014167554A3 (en) Composition and formulation of antimicrobial agents, processes thereof and methods for treating microbial infections
MY198214A (en) Fatty acid composition and use thereof
BR112016025208A2 (pt) concentrados de tensoativos para promover a umidificação do solo e crescimento de plantas
BR112014013098A2 (pt) composições compreendendo ácidos graxos que têm 20 carbonos e métodos de produção e uso dos mesmos
PE20141040A1 (es) Composicion farmaceutica que comprende un derivado de amida que inhibe el crecimiento de celulas con cancer y lubricante de sal no metalica
EA201990666A1 (ru) Способы получения свободных жирных кислот и производных жирных кислот из смешанного липидного исходного сырья или соапстоков
UY37856A (es) Mezclas inhibidoras de protoporfirinógeno oxidasas
BR112017011737A2 (pt) uso de derivados de óleos vegetais alcoxilados para reduzir o desvio na aplicação de agentes de tratamento de plantas
CO2017001088A2 (es) Mezcla de ácidos grasos y palmitoiletanolamida para su uso en el tratamiento de patologías inflamatorias y alérgicas
BR112017008033A2 (pt) composição farmacêutica para administração oral e respectivo processo de preparação
EA201591680A1 (ru) Смесь жирных кислот (гжк, группа жирных кислот) и её применение для лечения воспалительных патологий
NZ728643A (en) Efficient and scalable synthesis of 2-(1’h-indole-3’-carbonyl)-thiazole-4-carboxylic acid methyl ester and its structural analogs
CL2018002656A1 (es) Tabletas y polvos que contienen derivados de acido graso omega-3 y procedimientos para su producción.
AR099070A1 (es) Ácido (s)- 3-metil-abscísico y ésteres del mismo
MY177028A (en) Solid compositions of triglycerides and uses thereof
CO2017004968A2 (es) Alimentación a base de algas para ganado a dosis bajas para producir niveles altos de omega 3 en carne de res
CO2018012463A2 (es) Composición de lípidos en polvo que comprende una mezcla de sal
MX2018010235A (es) Mezclas de bispiribac.
PH12019500013A1 (en) Process for preparing fatty acids by ester hydrolysis
ES2527366A1 (es) Composición detergente que comprende un biosurfactante de origen vegetal
PH12015500793B1 (en) Control agent for plant pest and/or plant disease

Legal Events

Date Code Title Description
FD Application declared void or lapsed